LIGAND PHARMACEUTICALS INCORPORATED
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Nov 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $63.7M | — | $51.7M | — | — | — | $115.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $14.7M | — | $2.1M | — | — | — | $21.0M |
| SG&A Expense | — | $29.1M | — | $20.8M | — | — | — | $28.4M |
| Operating Income | — | $8.6M | — | $17.4M | — | — | — | $54.9M |
| Operating Margin | — | 13.5% | — | 33.6% | — | — | — | 47.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $64.3M | — | $-24.3M | — | — | — | $141.1M |
| Income Tax Expense | — | $15.8M | — | $-10.9M | — | — | — | $23.9M |
| Net Income | — | $48.5M | — | $-13.3M | — | — | — | $117.3M |
| Net Margin | — | 76.2% | — | -25.8% | — | — | — | 101.6% |
| EPS (Basic) | — | $2.42 | — | $-0.67 | — | — | — | $5.99 |
| EPS (Diluted) | — | $2.22 | — | $-0.67 | — | — | — | $5.68 |
| Shares Outstanding (Basic) | 19.9M | 20.1M | 20.0M | 19.9M | 19.9M | 19.8M | 19.7M | 19.6M |
| Shares Outstanding (Diluted) | 19.9M | 21.8M | 20.0M | 19.9M | 19.9M | 19.8M | 19.7M | 20.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |